Yogen Saunthararajah

25PUBLICATIONS
84CO-AUTHORS
Molecular targetsPredictive and prognostic markersHaematological tumoursEpidemiological modellingGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (25)

|Aug 20, 2026
FLT3-ITD signals for CEBPA and p53 proteolysis by the ubiquitin-proteosome pathway.

|Jul 10, 2026
H2BE113K mutation promotes breast cancer metastasis through modulating chromatin dynamics.

|Oct 08, 2025
Combining drugs that bypass p53 to treat TP53-mutated leukemias.

Sudipta Biswas, Zeinab Albadry M Zahran, Xiaorong Gu

|Sep 24, 2024
A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort.

Mendel Goldfinger, Ioannis Mantzaris, Aditi Shastri

|Jul 07, 2023
Pharmacokinetics and pharmacodynamics of an oral formulation of decitabine and tetrahydrouridine.

Henry Lau, Philip G Woost, Ute Friedrich

|Jun 21, 2023
A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AML.

David Levitz, Yogen Saunthararajah, Kateryna Fedorov

Pageof 5

Frequent Collaborators

4 joint publications

Babal K Jha

3 joint publications

Mendel Goldfinger

3 joint publications

Jaroslaw P Maciejewski

2 joint publications

Misam Zawit